Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1

An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringhen, Sara, Voorhees, Peter M., Plesner, Torben, Mellqvist, Ulf‐Henrik, Reeves, Brandi, Sonneveld, Pieter, Byrne, Catriona, Nordström, Eva, Harmenberg, Johan, Obermüller, Jakob, Richardson, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy – Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248157/
https://www.ncbi.nlm.nih.gov/pubmed/33403663
http://dx.doi.org/10.1111/bjh.17302
_version_ 1783716668478849024
author Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf‐Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordström, Eva
Harmenberg, Johan
Obermüller, Jakob
Richardson, Paul G.
author_facet Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf‐Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordström, Eva
Harmenberg, Johan
Obermüller, Jakob
Richardson, Paul G.
author_sort Bringhen, Sara
collection PubMed
description An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46‐month median overall survival (OS) follow‐up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time‐to‐next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long‐term clinical benefit in patients with RRMM.
format Online
Article
Text
id pubmed-8248157
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82481572021-07-02 Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1 Bringhen, Sara Voorhees, Peter M. Plesner, Torben Mellqvist, Ulf‐Henrik Reeves, Brandi Sonneveld, Pieter Byrne, Catriona Nordström, Eva Harmenberg, Johan Obermüller, Jakob Richardson, Paul G. Br J Haematol Haematological malignancy – Clinical An updated survival analysis was conducted for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46‐month median overall survival (OS) follow‐up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time‐to‐next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long‐term clinical benefit in patients with RRMM. John Wiley and Sons Inc. 2021-01-06 2021-06 /pmc/articles/PMC8248157/ /pubmed/33403663 http://dx.doi.org/10.1111/bjh.17302 Text en © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Haematological malignancy – Clinical
Bringhen, Sara
Voorhees, Peter M.
Plesner, Torben
Mellqvist, Ulf‐Henrik
Reeves, Brandi
Sonneveld, Pieter
Byrne, Catriona
Nordström, Eva
Harmenberg, Johan
Obermüller, Jakob
Richardson, Paul G.
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
title Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
title_full Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
title_fullStr Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
title_full_unstemmed Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
title_short Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
title_sort melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the phase ii study o‐12‐m1
topic Haematological malignancy – Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248157/
https://www.ncbi.nlm.nih.gov/pubmed/33403663
http://dx.doi.org/10.1111/bjh.17302
work_keys_str_mv AT bringhensara melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT voorheespeterm melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT plesnertorben melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT mellqvistulfhenrik melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT reevesbrandi melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT sonneveldpieter melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT byrnecatriona melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT nordstromeva melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT harmenbergjohan melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT obermullerjakob melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1
AT richardsonpaulg melflufenplusdexamethasoneinrelapsedrefractorymultiplemyelomalongtermsurvivalfollowupfromthephaseiistudyo12m1

Ejemplares similares